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Abstract
Background: Closure of patent ductus arteriosus (PDA), ventricular septal defect (VSD) and atrial septal defect (ASD) 
can be done surgically or by device. This study was designed to compare the total cost of surgical or device closures of PDA, 
ASD or VSD for Iranian patients.
Methods: This is a cross-sectional study, conducted from January 1, 2005 until January 1, 2006 in two large heart centers 
of Tehran. The study population consisted of 91 patients with isolated PDA, ASD or VSD who underwent either surgical or 
device closure.  
Results: PDA device closure either with the Amplatzer device or coil was less costly than that via surgery. VSD closure 
with the Amplatzer device was more costly (17.6%). Although ASD closure was also more expensive (15.4%), the difference 
was not statistically significant.
Conclusion: It can be concluded that PDA closure is cheaper than surgery in Iran. ASD and VSD device closures are more 
expensive, but the added cost can be affordable in view of the advantages of device closure.
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Introduction
Surgery was the standard treatment for patent ductus 
arteriosus (PDA), ostium secundum atrial septal defect 
(ASD) and ventricular septal defect (VSD) until the advent 
of transcatheter techniques. Nowadays, the transcatheter 
device closure of congenital cardiac defects is being used 
increasingly with excellent results.1
 A controversial issue in pediatric cardiology during the 
past decades has been the comparison of the transcatheter 
closure of PDA, ASD and VSD with surgery. Surgical closure 
is reserved for patients whose families choose surgical repair 
or whose lesions remain unsuitable for device closure.2 The 
alleged advantages of percutaneous occlusion over surgery 
can include avoidance of cardiopulmonary bypass (CBP) and 
its potential adverse sequelae, fewer complications, shorter 
hospital stay and superior cosmetic results.3
The cost-effectiveness of PDA, ASD and VSD transcatheter 
closure versus surgery is still a controversial issue in many 
countries.4
Comparisons of costs have yielded equivocal results in 
different countries and at different times. Relative professional 
The Journal of Tehran University Heart Center 
142
Ali Akbar Zeinaloo et al
fees for the interventionist and cardiac surgeon, cost of the 
device and length of hospital stay after the procedures can be 
the main determinants in this regard. Comparisons in terms 
of hospitalization have yielded shorter durations after device 
closure in almost all studies reported from different parts of 
the world.2-11
In Iran, cost implications are an important factor for patients 
or parents in choosing the right procedure. The Iranian 
government pays subsidies for intracardiac devices (around 
50% of the actual price); therefore, it can be difficult to make 
a comparison between the situation in Iran and that in the 
Western countries. To the best of our knowledge, no previous 
studies have compared the hospital costs of the procedures in 
Iran. We, therefore, sought to conduct the current study.    
       
Methods
We conducted a cross-sectional study of a randomized 
sample of 91 patients (40 patients with device closure and 
51 patients with surgical closure), who were hospitalized 
in two large public hospitals of Tehran. We recruited 
patients admitted for the surgical or device closure of the 
ostium secundum ASD, VSD or PDA at Shaheed Rajayee 
Cardiovascular Center (SRCVC) and Children’s Medical 
Center at Imam Khomeini Hospital Complex (CMC/IKHC). 
All the patients were hospitalized in the pediatric wards of 
these hospitals and were in the pediatric age group (under 
18 years of age). The study period was from January 1, 2005 
until January 1, 2006. The study was restricted to patients 
with isolated VSD (all types), ostium secundum ASD and 
PDA. The other inclusion criterion was Iranian citizenship as 
the subsidy is paid only for Iranian patients. The implanted 
devices included the Amplatzer Ductal Occluder (ADO), 
Amplatzer Septal Occluder (ASO), Amplatzer Membranous 
Ventricular Septal Occluder (AMVSO) (AGA Medical 
Corporation, Golden Valley, Minnesota, USA) and Nit-
Occlude coils (pfm AG, Köln, Germany).
The number of the patients that underwent each procedure 
is depicted in Table 1. Of the total patients, 76 (83.5%) were 
hospitalized and treated in SRCVC and 15 (16.5%) in CMC/
IKHC. All the VSDs were of the perimembranous type. 
There was no significant difference in terms of the age of the 
PDA or ASD patients (p values were 0.715, 0.415 and 0.283 
for ADO, coil and ASO patients, respectively, in comparison 
with relevant surgical patients). The VSD patients treated 
surgically were significantly younger than those treated 
with the device (4.34±4.77 and 16±2.94 years, respectively, 
for surgical and device closure groups, p value <0.001). 
Sex comparisons of the patients also yielded no significant 
differences (p values were 0.268, 0.637 and 0.162 for PDA, 
ASD and VSD patients, respectively).
Table 1. Number of patients enrolled per procedure
Surgery Amplatzer Coil
PDA 20 17 9
ASD 17 10 -
VSD 14 4 -
PDA, Patent ductus arteriosus; ASD, Atrial septal defect; VSD, Ventricular 
septal defect
The total cost for the patients or their parents were 
calculated including professional fees and device price. 
Comparisons of the detailed costs were beyond the scope of 
this study. Intraoperative transesophageal echocardiography 
was not performed for the surgical cases. All the costs were 
calculated before applying insurance discounts for the insured 
patients. The results were calculated in Iranian Rials and then 
converted to US dollars ($1=9200 Iranian Rials).
PDA and VSD device closures were successful in all the 
patients, but there was significant residual PDA after surgical 
ligation (5%) in one patient and significant residual VSD 
after surgery (7.1%) in another. ASD device closure was 
unsuccessful in one patient due to device embolization; the 
device was removed and the defect was repaired surgically. 
A similar situation occurred for a VSD device closure. Coil 
embolization occurred in one patient and was, subsequently, 
treated via repeated device occlusion. Other complications 
included postpericardiotomy syndrome (2 patients), apnea 
and cyanosis after the ADO implantation (1 patient), anemia 
requiring transfusion after the ADO implantation (1 patient), 
temporary complete heart block after VSD surgical closure 
(1 patient) and temporary supraventricular tachycardia after 
ASD surgical closure (3 patients). 
Intensive care unit (ICU) stay was shorter for both PDA 
device closure and ASD device closure than that for surgery 
(p values were <0.001, 0.005 and 0.025 for ADO, coil and 
ASO closures, respectively, in comparison with the relevant 
surgeries); however, there was no significant difference with 
respect to VSD device closure (p=0.141). Floor bed stay was 
longer for all kinds of surgical closures (p values were 0.007, 
0.038, 0.004 and 0.004 for ADO, coil, ASO and AMVSO 
closures, respectively, in comparison with the relevant 
surgeries). Comparisons of the hospitalization durations are 
shown in Table 2.
All the data were collected and analyzed using SPSS for 
Windows release 11.0.0 standard version. The independent-
Samples T, Fisher Exact and Pearson Chi-Square tests were 
utilized, and p values lower than 0.05 were considered 
significant. Otherwise specified, data are presented as 
mean±standard deviation. 
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Results
PDA closure with the ADO and pfm coil was less expensive 
than that via surgery (12% and 33%, respectively, with p 
values of 0.18 and 0.005, respectively). PDA closure with 
the coil was also cheaper than that with the ADO (p=0.046). 
ASD device closure had a non-significant cost difference with 
surgery (15.4% higher, p=0.269). VSD device closure was 
also more expensive than surgery (17.6%) with a significant 
difference (p<0.001). Comparisons of the total costs for 
PDA, ASD and VSD closures are shown in Table 3.
Table 3. Comparison of total costs (in US dollars) for PDA, ASD or VSD 
closures (surgery versus device occlusion)
Surgery Amplatzer Coil p value
PDA 1697±218 1494±264 1136±440   0.018 (Amplatzer), 
0.005 (Coil)
ASD 2739±615 3160±1051 -   0.269
VSD 2637±354 3102±76.7 - <0.001




There has been a debate over the cost-effectiveness of PDA 
device closure versus surgery over the past years. In 1993, 
Gray et al.5 from the USA reported that PDA device closure 
(Rashkind PDA occluder) was costlier than surgical closure 
($11466 for device closure versus $8838 for surgery). But 
in a later study published in 1996, Hawkins et al.6 from the 
USA showed that the cost of PDA coil occlusion ($7105) was 
almost the same as that of surgery ($7101).
 Since then, all studies comparing coil occlusion with 
surgery have yielded favorable results for the coil, including 
those of Kramer et al.12 from the USA ($4964 versus $2941), 
Agnetti et al.13 from Italy, Laohaprasitiporn et al.14 from 
Thailand, Vázquez-Antona et al.4 from Mexico ($6964 
versus $4412) and Prieto et al.7 from USA ($8509 versus 
$5273). Vázquez-Antona et al.4 also compared Amplatzer 
device occlusion with surgery and found that the costs were 
almost the same ($6964 for surgery versus $6815 for device 
occlusion). The reason for this trend is apparently the lower 
cost of newer devices. 
It is now accepted that PDA coil occlusion is less costly 
than surgery wherever it is practiced.
The relative cost of PDA occlusion with the ADO is 
controversial in developing countries, where the professional 
fees for surgery or intervention are relatively low in 
comparison with the device cost; the cost difference in these 
countries, therefore, cannot be considerable. The present 
study also demonstrates that PDA device closure, whether 
with the ADO or with the coil, is cheaper than surgery in 
Iran. Professional fees are relatively low in Iranian public 
hospitals, but what makes ADO closure more affordable 
is probably the subsidy that Iranian government pays for 
intracardiac devices (around 50% of the actual price).
 As we mentioned earlier, the cost-effectiveness of ASD 
closure is something of an enigma: ASD device closure maybe 
more or less expensive than surgery in different countries 
even when the same device (ASO) is used at relatively the 
same time. The reports that are in favor of surgery include 
those of Durongpisitkul et al. from Thailand (Durongpisitkul 
K, Soongswang J, Laohaprasitiporn D, Nana A, Sriyoschati 
S, Ponvilawan S, Subtaweesin T, Kangkagate C. Comparison 
of atrial septal defect closure using Amplatzer septal occluder 
with surgery[Abstract]. Proceedings of the 3rd World 
Congress of Pediatric Cardiology and Cardiac Surgery, 
Toronto, Canada 2001:830.) and Vida et al.3 from Guatemala 
($3330 versus $4521). Thompson et al.8 from the UK arrived 
at almost equal costs (£5375 for ASO versus £5412 for 
surgery). In contrast, there are reports in favor of device 
occlusion, including those of Galal et al. from Switzerland 
(Galal MO, von Bremen K, Sekarski N, Payot M, Bernath M, 
Corno A, Hurni M, von Segesser L, Fanconi S, Kappenberger 
L. Cost-comparison of transcatheter and surgical closure of 
atrial septal defect in children[Abstract]. Proceedings of the 
3rd World Congress of Pediatric Cardiology and Cardiac 
Surgery, Toronto, Canada, 2001: 878.), Kim and Hijazi9 from 
USA ($25126 versus $39351), Hughes et al.2 from Australia 
(Aus$11845 versus Aus$12969) and Khelashvili et al.10 from 
Georgia. The present study also shows statistically non-
significant higher costs of ASD device closure ($3102 versus 
$2637, 15.4% higher) in Iran. 
VSD device closure is the least studied device closure 
in terms of cost comparison. In the only other study in the 
existing medical literature, Xunmin et al.11 found a non-
significant difference between the two methods of VSD 
Table 2. Comparison of the length of hospital stays (in days) for PDA, ASD or VSD closures (surgery versus device occlusion)* 
Surgery Amplatzer Devices Coil p value







PDA 9.10±6.10 1.30±0.73 4.71±1.69 0.35±0.49 4.56±1.81 0.56±0.53 0.007 <0.001 0.038 0.005
ASD 12.8±8.36 3.65±3.24 4.20±2.62 1.60±0.97 - - 0.004 0.025 - -
VSD 12.4±8.09 3.29±2.30 4.50±2.08 1.50±1.73 - - 0.004 0.141 - -
*Data are presented as mean±SD
PDA, Patent ductus arteriosus; ASD, Atrial septal defect; VSD, Ventricular septal defect; ICU, Intensive care unit; Amp, Amplatzer devices
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closure, albeit Amplatzer device closure was 10% more 
costly (¥48521 versus ¥44058). The current study found 
17.6% higher costs, which is not far from the results of the 
above-mentioned study.
 It should be reemphasized that the Iranian government 
pays subsidies for the devices and the calculated costs include 
the discounted fees for the implanted devices. But it should 
be noticed that subsidy is also paid for some materials used 
in the operating room. Cost calculation without considering 
these subsidies would be difficult and only performable 
based on the limited number of foreign patients for whom no 
subsidy is granted.
Although we tried to calculate all possible payments, 
there may be some other charges not included in the hospital 
documents. In addition, the costs related to time away from 
work or school was not included in the study. It is deserving of 
note, however, that most of the other similar studies have also 
not included this factor due to the difficulty in assessment. 
Conclusion
PDA device closure either with the pfm Nit-Occlud coil or 
ADO is less costly than surgical ligation in Iran. Although 
ASD and VSD device closures are more expensive than their 
respective surgeries, the added costs can be affordable for the 
patients and their parents considering the benefits of device 
closure. 
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